Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
The process of introducing a new medication to the market, starting from initial development to the final launch, is both time-intensive and heavily regulated, often spanning over a decade or more. Achieving success in this endeavor hinges on the timely availability of precise analytical data, which is essential for making informed decisions during the early stages of development and reducing the likelihood of setbacks later on. Modern drug development primarily follows a systematic approach, with the crucial first step usually being the identification of a biological target to concentrate efforts on. This target identification demands a comprehensive understanding of the characteristics of the candidates, enabling swift and reliable identification of the most promising options. After establishing a biological target, the next significant hurdle is identifying the most advantageous lead molecules, which entails discovering potential drug candidates—these may include small organic compounds or biological constructs with therapeutic capabilities. Thus, the entire journey from concept to market is a complex interplay of scientific insight and strategic decision-making.
Description
Harnessing RNA sequencing (RNA-seq) data alongside Artificial Intelligence presents both a crucial necessity and a significant opportunity for creating therapies aimed at correcting splicing errors. By leveraging machine learning, we can uncover novel splicing errors and swiftly formulate therapeutic compounds to address them. Our AI platform, SpliceCore, is specifically designed for discovering RNA therapeutics. This cutting-edge technology focuses on analyzing RNA sequencing data with unparalleled efficiency. It can swiftly identify, evaluate, and validate potential drug targets, outpacing traditional methodologies. Central to SpliceCore is our unique repository containing over 5 million potential RNA splicing errors, making it the largest of its kind globally and instrumental for testing any RNA sequencing dataset submitted for analysis. The integration of scalable cloud computing allows us to handle vast quantities of RNA sequencing data in a way that is not only efficient but also cost-effective, significantly speeding up the pace of therapeutic advancements. This innovative approach promises to revolutionize the landscape of RNA therapeutics.
API Access
Has API
No
API Access
Has API
No
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
Yes
Live Rep (24/7)
No
Online Support
Yes
Types of Training
Training Docs
No
Webinars
Yes
Live Training (Online)
No
In Person
No
Types of Training
Training Docs
Yes
Webinars
No
Live Training (Online)
No
In Person
Yes
Vendor Details
Company Name
Bruker
Founded
1960
Country
United States
Website
www.bruker.com/en/applications/pharma/drug-discovery.html
Vendor Details
Company Name
Envisagenics
Founded
2014
Country
United States
Website
www.envisagenics.com/platform/